Martin Markowitz MD

Infectious Disease•New York, NY

Clinical Director and Staff Investigator ADARC Aaron Diamond Professor at the Rockefeller U.

Join to View Full Profile

455 1st Ave# 7New York, NY 10016
Phone+1 212-448-5020
Fax+1 212-725-1126

Education & Training

NYU Grossman School of MedicineFellowship, Infectious Disease, 1991 - 1994
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1981 - 1984
University of California (San Francisco)/Mount ZionResidency, Internal Medicine, 1978 - 1980
Stanford University School of MedicineClass of 1978

Certifications & Licensure

NY State Medical License 1981 - 2025
FL State Medical License 1990 - 1998
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years
Completed
Phase 1
Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients
Completed
Not Applicable
Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV Start of enrollment: 2004 Feb 01
Completed
Phase 2
Long-term Follow-up of HIV Infected Patients Identified During Early Infection Start of enrollment: 2003 Jul 01
Completed
Observational Study of Treated and Untreated Acute and Early HIV-1 Infection Start of enrollment: 2002 Feb 01
Completed
Phase I/II, Open-Label Trial of Three Monoclonal Antibodies Start of enrollment: 2003 Oct 01
Completed
Phase 1, Phase 2
Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01) Start of enrollment: 2007 Oct 01
Completed
Not Applicable
Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc Start of enrollment: 2007 Sep 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

18 citations
Y RNAs are conserved endogenous RIG-I ligands across RNA virus infection and are targeted by HIV-1.
Nicolas Vabret, Valérie Najburg, Alexander Solovyov, Ramya Gopal, Christopher McClain
Iscience. 2022-07-15
27 citations
Once-Weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques From Intrarectal Challenge With SHIV109CP3.
Martin Markowitz, Agegnehu Gettie, Leslie St. Bernard, Chasity D. Andrews, Hiroshi Mohri
The Journal of Infectious Diseases. 2020-04-07
39 citations
Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1.
Martin Markowitz, Jay A. Grobler
Current Opinion in HIV and AIDS. 2020-01-01

Press Mentions

HIV Eradication Goals Stuck Between Perfect and RealisticJanuary 3rd, 2019